Mark Middlemas is the CEO and Founder responsible for building, supporting and promoting all of the talent in our unique community. Mark is a former Director of IPG’s Universal McCann where he managed the advertising and sponsorship programs for some of the world’s biggest brands including Coca-Cola GB, Mastercard, Bacardi-Martini, XBox & Royal Mail Group. He is a keen ultra runner, two-time Marathon des Sables finisher and completed the ForRangers Ultra in Kenya in 2018.
ATHLETE ADVISORY BOARD
Simon Shaw MBE represented Wasps, Toulon, England and the British & Irish Lions, and was a member of the 2003 England Rugby World Cup winning squad. Now a businessman and investor, Simon is advising The Athlete Media Group on strategy and introducing us to his vast network of fellow athletes, brands and rights holders. He remains the only second row to have ever dropped a goal in the Premiership.
Iona Stephen is a professional golfer and athletic role model. She played four sports at junior international level before taking to golf while at university. In 2016, Iona turned professional and made her debut on the Ladies European Tour later that year at the Qatar Ladies Masters. Iona is introducing her athlete network to The Athlete Media Group, as well as advising on product and strategy.
BUSINESS ADVISORY BOARD
Professor Piers Daubeney MA DM FRCP FRCPCH DCH trained in medicine at Oxford University and St Thomas’ Hospital gaining Honours in Therapeutics and Clinical Pharmacology. He specialised as a paediatric cardiologist working at the Royal Brompton Hospital and is Professor of Practice (paediatric cardiology) at Imperial College. He has written more than 50 scientific papers and edited 2 books. He jointly founded and is also CEO of The Congenital and Children’s Heart Centre (www.childrensheartcentre.com) providing private medical and surgical care to children and adults with congenital heart disease with large national and international referral base.
Professor Daubeney is also the Chief Executive Officer of DMNoMore, a company dedicated to developing curative treatments for auto-immune diseases. The company is developing a range of novel therapeutic innovations including an exciting new vaccine to treat and prevent diabetes and a predictive kit for first-degree relatives. Our long-term goal is the broadening of our platform approach to other autoimmune diseases through our active R & D programme. He is responsible for the day to day running of the Company as well as future business development and strategy.
Philip Daubeney MA (Oxon) was for many years the CEO of ICI Africa and Asia (forerunner of AstraZeneca) that included responsibility for their pharmaceutical interests. During this period he undertook a large number of corporate mergers, acquisitions and company disposals. He then became CEO at the Electricity Association and Non-Executive Chairman of the JP Morgan Indian Investment Trust. He is currently Non-Executive Chairman of the International Air Compressors Association and Chairman of AFNOR UK, a subsidiary of AFNOR France, the French Standards Body. He brings significant expertise in corporate governance, compliance and a proven track record in the development and then sale of individual corporate entities.